Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REVERT Study: A Phase 1b/2a Study to Assess the Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1

NCT07040436 is registered in ClinicalTrials.gov with Oncodesign Precision Medicine as lead sponsor.

NCT NCT07040436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07040436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REVERT Study: A Phase 1b/2a Study to Assess the Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1
Lead sponsor
Oncodesign Precision Medicine
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
September 30, 2025
Completion date
December 31, 2027
Enrollment
41 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma